Early Phase 1 Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a condition called NMOSD (Neuromyelitis Optica Spectrum Disorder) and have tested positive for a specific antibody called anti-AQP4 in a screening blood test.
- You have had at least 1 documented relapse (a flare-up of symptoms) in the 12 months before joining the study.
- Your level of disability, as measured by a standard neurological scale, falls within a certain range — from no disability to moderate-to-severe disability (confirm with trial site).
- You are between 18 and 70 years old at the time you give your consent to join.
Who may not be able to join:
- You have received certain medications used to treat MS or similar conditions (such as natalizumab, fingolimod, or others) within the 6 months before the study starts.
- You have taken certain immune-suppressing drugs or biological treatments (such as azathioprine, methotrexate, or tocilizumab) within 3 months before the first dose of the study treatment.
- You have another serious uncontrolled illness, such as a heart condition, blood disorder, lung disease, kidney disease, or a severe immune deficiency.
- You have had a known active infection within 3 months before the study starts.
- You are currently pregnant or breastfeeding.
- You have had a severe allergic reaction to a biological medicine in the past.
- You have chronic active hepatitis B or hepatitis C.
- You have active tuberculosis (TB).
- Your blood test results at screening show abnormal levels of certain blood cells or liver-related markers (confirm with trial site).
- You have had a problem with drug or alcohol misuse within the 6 months before the study starts.
- You have received a live vaccine within 4 weeks before the study starts.
- You have uncontrolled high blood pressure, diabetes, or other uncontrolled ongoing health conditions.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fu-Dong Shi, MD,PhD, Tianjin Medical University General Hospital
Phone: 022-60814587
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability].
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.